Use of antidementia drugs in frontotemporal lobar degeneration

American Journal of Alzheimer's Disease and other Dementias

Volumn 27, Issue 4, 2012, Pages 260-266

  López Pousa, Secundino ^a,b   Calvó Perxas, Laia ^a   Lejarreta, Saioa ^b   Cullell, Marta ^c   Meléndez, Rosa ^d   Hernández, Erélido ^e   Bisbe, Josep ^f   Perkal, Héctor ^g   Manzano, Anna ^h   Roig, Anna Maria ⁱ   Turró Garriga, Oriol ^a   Vilalta Franch, Joan ^a,b   Garre Olmo, Josep ^{a,b,c,d,e,f,g,h,i,j}  

^a Hospital de Santa Caterina   (Spain)

^b HOSPITAL SANTA CATERINA   (Spain)

^c HOSPITAL DE FIGUERES   (Spain)

^d Hospital Universitari Dr Josep Trueta de Girona   (Spain)

^e Hospital de Palamos   (Spain)

^f Hospital Comarcal Sant Jaume d'Olot   (Spain)

^g Hospital Comarcal de Blanes   (Spain)

^h Hospital Comarcal de Campdevànol   (Spain)

ⁱ Pharmacy Unit   (Spain)

^j UNIVERSITY OF GIRONA   (Spain)

more..

Author keywords

Alzheimer's disease; donepezil; frontotemporal dementia; galantamine; memantine; rivastigmine; treatment

Indexed keywords

ALPRAZOLAM; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; ARMODAFINIL; ATOMOXETINE; BENTAZEPAM; BENZODIAZEPINE; BROMAZEPAM; CHOLINESTERASE INHIBITOR; CLOBAZAM; CLORAZEPATE; DIAZEPAM; FLUNITRAZEPAM; FLURAZEPAM; GALANTAMINE; HALOPERIDOL; HYPNOTIC AGENT; KETAZOLAM; LISDEXAMFETAMINE; LORAZEPAM; LORMETAZEPAM; MEMANTINE; MODAFINIL; NEUROLEPTIC AGENT; NOOTROPIC AGENT; PSYCHOSTIMULANT AGENT; RISPERIDONE; RIVASTIGMINE; SEDATIVE AGENT; UNINDEXED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BIVARIATE ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIMARY PROGRESSIVE APHASIA; REGISTER;

EID: 84863484056     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317512447887     Document Type: Article

References (33)

1. Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia. 2000;15(3):93-101. (Pubitemid 30340226)
2. Hachinski V. Shifts in thinking about dementia. JAMA. 2008;300: 2172-2173.
3. Braak H, Braak E. Neuropathological staging of Alzheimerrelated changes. Acta Neuropathol (Berl). 1991;82(4):239-259.
4. Braak H, de Vos RA, Jansen EN, Bratzke H, Braak E. Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Prog Brain Res. 1998;117:267-285. (Pubitemid 28530695)
5. Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16(4):203-212. (Pubitemid 35434796)
6. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol. 2001;58(1):1803-1809. (Pubitemid 33044246)
7. Toribio-Díaz ME, Morera-Guitart J. Clasificación clínica y biomolecular de las demencias frontotemporales. Rev Neurol. 2008; 47(11):588-598.
8. Mega M, Cummings JL. Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci. 1994;6(4): 358-370. (Pubitemid 24344856)
9. Ratnavalli E, Brayne C, Dawson K, Hodges JR. La prevalencia de la demencia frontotemporal. Neurología. 2002;58(11):1615-1621.
10. Trojanowski JQ, Dickson D. Update on the neuropathological diagnosis of frontotemporal dementia. J Neuropathol Exp Neurol. 2001;60(12):1123-1126. (Pubitemid 33117093)
11. Massoud F, Léger GC. Pharmacological treatment of Alzheimer disease. Can J Psychiatry. 2011;56(10):579-588.
12. Larner AJ. Cholinesterase inhibitors: beyond Alzheimer's disease. Expert Rev Neurother. 2010;10(11):1699-1705.
13. O'Brien JT, Burns A; BAP Dementia Consensus Group. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(8):997-1019.
14. German RR, Armstrong G, Birkhead GS. Surveillance coordination Group. Updated guidelines for evaluating public health surveillance systems. MMWR Recomm Rep. 2001;50(RR-13): 1-35.
15. Garre-Olmo J, Flaqué M, Gich J, et al. Clinical registry of dementia based on the principle of epidemiological surveillance. BMC Neurol. 2009;9:5.
16. Garre-Olmo J, Genis-Batlle D, del Mar Fernandez M, et al. Incidence and subtypes of early-onset dementia in a geographically defined general population. Neurology. 2010;75(14):1249-1255.
17. López-Pousa S, Garre-Olmo J, Monserrat-Vila S, et al. Propuesta para un registro clínico de demencias. Rev Neurol. 2006;43(1):32-38.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
19. Folstein MF, Folstein SE, McHugh PR. Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
20. Blessed G, Tomilson BE, Roth M. The association between quantitative measures of dementia, and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114(512): 797-811.
21. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414. (Pubitemid 23346995)
22. Bei Hu, Ross L, Neuhaus J, et al. Off-label medication use in fronto-temporal dementia. Am J Alzheimers Dis Other Demen. 2010;25(2): 128-133.
23. Kaye ED, Petrovic-Poljak A, Verhoeff NP, Freedman M. Fronto-temporal dementia and pharmacologic interventions. J Neuropsychiatry Clin Neurosci. 2010;22(1):19-29.
24. Portugal Mda G, Marinho V, Laks J. Tratamiento farmacológico de la frontotemporal la degeneración lobar: revisión sistemática. Rev Bras Psiquiatr. 2011;33(1):81-90.
25. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. Can Med Assoc J. 2002;167(11): 1269-1270. (Pubitemid 35370646)
26. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. Can Med Assoc J. 2004; 170(9):1395. (Pubitemid 38594631)
27. Vilalta-Franch J, López-Pousa S, Garre-Olmo J, Turon-Estrada A, Pericot-Nierga I. Mortalidad en pacientes con enfermedad de Alzheimer tratados con neurolépticos atípicos. Rev Neurol. 2008; 46(3):129-134. (Pubitemid 351397735)
28. Dolder CR, Davis LN, McKinsey J. Use of psychostimulants in patients with dementia. Ann Pharmacother. 2010;44(10): 1624-1632.
29. Huey ED, Putnam KT, Grafman J. A systematic review of neuro-transmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66(1):17-22. (Pubitemid 43739585)
30. Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21(14):931-937. (Pubitemid 39626373)
31. Lampl Y, Sadeh M, Lorberboym M. Efficacy of acetylcholinesterase inhibitors in frontotemporal dementia. Ann Pharmacother. 2004;38(11):1967-1968. (Pubitemid 39425737)
32. Mendez MF, Shapira JS. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15(1):84-87. (Pubitemid 46106094)
33. Kertesz A, Morlog D, Light M, et al. Galantamine in fronto-temporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25(2):178-185. (Pubitemid 351196131)